Last reviewed · How we verify

Dexamethasone dimenhidrinate

Yeditepe University Hospital · FDA-approved active Small molecule Quality 2/100

Dexamethasone dimenhidrinate is a Small molecule drug developed by Yeditepe University Hospital. It is currently FDA-approved. Also known as: dekort dramamin.

At a glance

Generic nameDexamethasone dimenhidrinate
Also known asdekort dramamin
SponsorYeditepe University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexamethasone dimenhidrinate

What is Dexamethasone dimenhidrinate?

Dexamethasone dimenhidrinate is a Small molecule drug developed by Yeditepe University Hospital.

Who makes Dexamethasone dimenhidrinate?

Dexamethasone dimenhidrinate is developed and marketed by Yeditepe University Hospital (see full Yeditepe University Hospital pipeline at /company/yeditepe-university-hospital).

Is Dexamethasone dimenhidrinate also known as anything else?

Dexamethasone dimenhidrinate is also known as dekort dramamin.

What development phase is Dexamethasone dimenhidrinate in?

Dexamethasone dimenhidrinate is FDA-approved (marketed).

Related